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Abstract
A 58-year-old, non-smoking female of Philippine origin presented with painful thoracic and neck
nodal relapse of lung adenocarcinoma almost 5 years after left pneumonectomy for stage II non-
small-cell lung cancer. She refused conventional chemotherapy or radiation because of toxicity
concerns, but agreed to oral erlotinib 150 mg/day. Within weeks, her pain was well controlled, with
softening of palpable neck nodes. Repeat scans after 7 months on erlotinib showed partial response
of thoracic disease and nodal metastases. This response was maintained for 11 months on erlotinib,
with symptomatic progression at the original sites of relapse by 15 months. Erlotinib was well
tolerated, with grade 2–3 rash, and grade 1 dry cough and diarrhoea being the only significant
toxicities. Importantly, the patient was able to maintain daily activities throughout erlotinib therapy.
Background
For patients diagnosed with non-small cell lung cancer
(NSCLC), platinum-based chemotherapy is frequently
used as a first-line treatment [1,2]. Most patients will
eventually exhibit signs of disease progression following
first-line chemotherapy, and a second line of therapy may
be required to control tumour growth. In a phase III trial,
the epidermal growth factor receptor (EGFR) inhibitor
erlotinib has been shown to significantly prolong sur-
vival, delay symptom deterioration, and provide quality-
of-life benefits for patients who experienced disease pro-
gression following first-line chemotherapy [3,4].
Due to the cytotoxic effects of chemotherapy, some
patients may be considered unsuitable for chemotherapy
or may decline chemotherapy as a first-line treatment. In
these circumstances, erlotinib may be used as an alterna-
tive and less toxic first-line therapy. This report describes
the case of a NSCLC patient who had a prolonged radio-
logical and symptomatic response to first-line erlotinib
therapy.
Case report
A 58-year old non-smoking female, of Philippine origin
but domiciled in Australia, presented in December 2000
with cough and wheeze that was not responsive to inhaled
beta-agonists. Chest radiography followed by computer-
ised tomography (CT) showed a stage II left perihilar lung
tumour, which was confirmed as NSCLC with adenocarci-
noma histology by fine needle biopsy. The patient was
otherwise well, but had a past history of chronic endome-
triosis. Her non-smoking mother died of lung cancer at
the age of 72, but there was no other family history of can-
cer. The primary lung tumour and hilar nodes were suc-
cessfully removed by left pneumonectomy in January
2001. The patient declined adjuvant chemotherapy or
radiation, because of concerns about toxicity.
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In August 2005 the patient returned to her respiratory
physician with weight loss, enlarged left neck lymph
nodes, and upper left neck and thoracic pains not control-
led by paracetamol and codeine. CT scan showed adeno-
carcinoma (confirmed on needle biopsy) in the left
cervical nodes (> 2.5 cm), a 3.3 cm mass at the left pneu-
monectomy stump, a 1.2 cm right middle lobe lung
lesion, and possible liver metastases up to 1.8 cm in size.
Transdermal fentanyl patches were commenced for pain
relief but the patient again declined cytotoxic chemother-
apy or radiation because of toxicity concerns. Erlotinib
was, therefore, recommended as an alternative to chemo-
therapy.
The patient started oral erlotinib 150 mg/day in Septem-
ber 2005, and within weeks noticed softening of the left
cervical nodes, and a decrease in pain, beyond that
achieved with opiates. She developed the facial and ante-
rior neck rash typical of EGFR inhibitors, with progression
to a grade 3 reaction. The rash did not resolve with topical
emollients or corticosteroids, but the patient decided to
continue therapy and the rash spontaneously resolved to
grade 2 in the next few months. Grade 1 dry cough and
mild diarrhoea were also noted, which both persisted
throughout. Repeat CT scan in January 2006 showed res-
olution of the liver lesions and a decrease in both thoracic
lesions; there was no change in the mediastinal or left
neck nodes. By May 2006, the cervical nodes had
decreased below 1 cm diameter, the left pneumonectomy
stump mass was 1.6 cm, and there were no new lesions,
consistent with a partial response.
In August 2006, after 11 months of erlotinib therapy,
there was radiographic progression, with an increase in
the left stump mass to 1.8 cm and the right middle lobe
lesion to 1.4 cm. However, there were no new lesions, and
the patient remained on erlotinib with an absence of new
symptoms. By December 2006, the left cervical nodes had
enlarged further, and the patient had increased pain in her
left neck and upper thorax. At this time, erlotinib was dis-
continued and the patient agreed to start conventional
chemotherapy with paclitaxel and carboplatin, which pro-
duced a partial response and symptomatic benefit. Since
January 2008, the patient has been receiving palliative
care, with the latest follow up in October 2008.
Discussion
Chemotherapy options for advanced NSCLC are associ-
ated with haematological toxicity that may reduce
patients' quality of life (QoL), or necessitate hospitalisa-
tion. As a consequence, many patients are either unsuita-
ble or, as in the case described here, unwilling to receive
chemotherapy. Erlotinib, a potent inhibitor of EGFR tyro-
sine-kinase activity has similar efficacy to second-line
chemotherapy options but a more favourable tolerability
profile [5]. In the BR.21 phase III trial, erlotinib provided
a significant survival benefit over placebo in patients with
advanced NSCLC who had previously received chemo-
therapy (hazard ratio 0.70, 95% confidence intervals
0.58–0.85, p < 0.001) [3], leading to regulatory approvals
in this setting. Erlotinib is currently under investigation as
a front-line treatment for advanced NSCLC, and several
phase II studies of first-line erlotinib monotherapy have
been reported, with promising results observed in both
selected and unselected patient populations [6-9]. Ongo-
ing studies also seek to determine which patients are most
likely to obtain a clinical benefit from first-line erlotinib
therapy. In the BR.21 study, female gender, adenocarci-
noma histology, never smoking status, and Asian ethnic-
ity were associated with a significantly greater likelihood
of response to erlotinib. The patient described in this
report had all of these characteristics and obtained a pro-
longed radiographic and symptomatic response to first-
line erlotinib. However, these demographic and clinical
characteristics do not provide criteria for selecting patients
to receive erlotinib; in the BR.21 study, survival benefits
were observed in almost all patient subgroups studied,
including in male former/current smokers with squa-
mous-cell carcinoma, a group that would be expected to
have a low tumour response rate [3,10]. Tumour molecu-
lar markers, particularly EGFR protein expression, EGFR
gene copy number and the presence of mutations in the
EGFR tyrosine-kinase domain, have also been studied to
determine which patients are most likely to benefit from
erlotinib therapy [11]. However, none of these factors
were significantly associated with survival on erlotinib
therapy in the BR.21 trial, and further investigation is
required [12,13]. Therefore, at present there are no relia-
ble criteria for selecting patients to receive erlotinib ther-
apy.
Rash and diarrhoea were the only significant toxicities
observed in the current case, and are the most common
toxicities associated with erlotinib. These toxicities are
generally mild or moderate and easily managed [3,14].
Furthermore, as seen in this case, rash often resolves to a
lower grade without any need for dose modification. In
addition to having a favourable tolerability profile, erlo-
tinib provides significant symptom and QoL benefits
[3,4]. The patient described here obtained 15 months of
relief from cancer-related pain on erlotinib therapy, while
maintaining most daily activity. Such improvements in
symptoms and QoL are highly valued by patients, even in
the absence of survival benefits [15].
Conclusion
In conclusion, this report describes an impressive radio-
logical and symptomatic response in a patient receiving
first-line erlotinib for advanced NSCLC. Erlotinib is,
therefore, an attractive option for NSCLC therapy.Publish with BioMed Central    and   every 
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